Filters:
788 Projects | 542 Researchers | $368,636,115 Invested
2025
Sunbird Bio
Mario Morken, MS/MBA
Proof-of-Principal clinical study for blood based extracellular vesicle bound biomarker signatures quantifying brain alpha synuclein aggregation state
2024
Alamar Biosciences
Xiao-Jun Ma, PhD
Development of ARGO DX™ for a new generation of blood-based diagnostics for Alzheimer’s disease and related neurodegenerative diseases
2024
Polku Therapeutics
Timo Myöhänen, PhD
Novel prolyl oligopeptidase ligands to target Tau in frontotemporal dementia and other tauopathies
2024
ViewMind
Yaakov Stern, PhD
Investigating ViewMind ocular digital cognitive biomarkers and their relationship to tau and amyloid PET scans.
2024
neotiv GmbH
David Berron, PhD
Integration of the neotiv digital cognitive assessments in the Swedish REAL AD study to screen and monitor preclinical Alzheimer’s disease
2024
NSC-Therapeutics GmbH
Manfred Windisch, PhD
A 2-Part, phase 2a, Multi-Center, randomised, double blinded, placebo controlled clinical trial investigating safety and tolerability, PK and exploratory efficacy of the M1 selective rigid, orthosteric M1 agonist NSC001 in patients suffering from mild to moderate Alzheimer’s Disease
2024
Aquinnah Pharmaceuticals
Glenn Larsen, PhD
Development of Orally Available, Brain Penetrant Compound Reducing Tau Pathology.
2024
C2N Diagnostics
Joel Braunstein, MD, MBA
Validation of a Mass Spectrometry-Based Clinical Lab Workstation and Global Scale-up of Precivity(TM) In-Vitro Diagnostic Testing
2024
Stichting Amsterdam UMC
Betty Tijms
Plasma proteomic approach to identify CSF defined molecular subtypes of Alzheimer’s disease for personalised treatment
2024
University of Gothenburg
Henrik Zetterberg, MD, PhD
Certified Reference Material and Method for plasma p-tau217
View More